ALYFTREK™, the ALYFTREK logo, JOURNAVX™and the JOURNAVX logo are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. +1.617.341.6100
ALYFTREK™, the ALYFTREK logo, JOURNAVX™and the JOURNAVX logo are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. +1.617.341.6100
ALYFTREK™, the ALYFTREK logo, JOURNAVX™and the JOURNAVX logo are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners. +1.617.341.6100 Cookie Preference Center ...
ALYFTREK™ , the ALYFTREK logo, JOURNAVX™ and the JOURNAVX logo are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks referenced herein are the property of their respective owners.News Stay current on all things Vertex and discover the latest news, information and update...
2, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2021 and raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion. "Our financial performance in the third quarter was outstanding,...
Learn about how small molecules can potentially make a big impact on the future of medicine. They are just one of our tools that are being investigated to unlock new ways to impact serious diseases. Learn more Corporate Responsibility Boston Learning Lab: Our high school summer internship 1 min...
we are working on them compliantly to provide them with information that they need, such as the full clinical profile of the medicine. Obviously, now, we also have the established price, which is an important component for them as well. And we do have indications that people are looking to...
Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex.“VX-548 has demonstrated a positive benefit-risk profile in Phase 2 and we are working with urgency to bring forward a medicine that delivers effective pain control without addictive potential to patients who are...
Learn why the Vertex Pharmaceuticals approach to career growth is unique from Chief Human Resources Officer Stephanie Franklin. Learn more Culture and Careers Vertex celebrates its 2022 Working Parents of the Year honorees 5 min read Vertex is proud to share that it has been named — once again...
$Editas Medicine(EDIT)$与VertexPharmaceuticals达成的Cas9许可协议项下的某些未来许可费和其他款项出售给DRI Healthcare Trust的全资子公司。 根据协议条款,Editas Medicine(EDIT)将获得5700万美元的预付现金,作为交换,Editas Medicine将支付高达100%的未来年度许可费,每年从500万美元到4000万美元不等。$达安基因(SZ002030...